You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CLINICAL TRIALS PROFILE FOR OXYBUTYNIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OXYBUTYNIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00170768 ↗ Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over Completed Novartis Phase 2 2005-02-01 The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
NCT00175123 ↗ Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status Aarhus University Hospital Phase 4 2005-05-01 The purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. The trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. The purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. The aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. The hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder.
NCT00175123 ↗ Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status University of Aarhus Phase 4 2005-05-01 The purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. The trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. The purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. The aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. The hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OXYBUTYNIN

Condition Name

Condition Name for OXYBUTYNIN
Intervention Trials
Overactive Bladder 20
Hyperhidrosis 8
Urinary Incontinence 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OXYBUTYNIN
Intervention Trials
Urinary Bladder, Overactive 32
Urinary Incontinence 13
Enuresis 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OXYBUTYNIN

Trials by Country

Trials by Country for OXYBUTYNIN
Location Trials
United States 194
Japan 20
Canada 12
Spain 6
Brazil 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OXYBUTYNIN
Location Trials
North Carolina 11
California 10
Georgia 10
Ohio 8
Michigan 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OXYBUTYNIN

Clinical Trial Phase

Clinical Trial Phase for OXYBUTYNIN
Clinical Trial Phase Trials
Phase 4 25
Phase 3 24
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OXYBUTYNIN
Clinical Trial Phase Trials
Completed 62
Recruiting 11
Not yet recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OXYBUTYNIN

Sponsor Name

Sponsor Name for OXYBUTYNIN
Sponsor Trials
Watson Pharmaceuticals 7
Mylan Pharmaceuticals 6
Pfizer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OXYBUTYNIN
Sponsor Trials
Other 79
Industry 47
U.S. Fed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.